NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
NewAmsterdam Pharma's Obicetrapib shows promise in Alzheimer's trials, with potential label expansion on the horizon. Meanwhile, the company addresses 'anti-statin' influencers regarding its lipid-lowering therapies.
About NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is a stock in the healthcare sector.
NewAmsterdam Pharma Company N.V. Ordinary Shares uses the ticker $NAMS for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) social dominance is up 265.56% from the previous week.
- NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) engagements is up 203.47% from the previous week.
Price: $34.60
Price 24-Hour Time-Series Raw Data
The stock is trading near its 52-week high, driven by acquisition rumors and positive market sentiment. A recent minor dip is likely due to profit-taking after the upward trend.
24-Hour: -1.68% 7-Day: -1.06% 30-Day: 9.42%
1-Year High: $41.50 on 2025-11-26
1-Year Low: $14.90 on 2025-04-10
AltRank: [-----]
AltRank 24-Hour Time-Series Raw Data
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is currently AltRank #1,199 based on combined combined social and market metrics
Daily Average: [---]
[--] Week: [-----] [------]
[--] Month: [-----] +1,254
[--] Months: [-----] +441
[--] Year: [-----] +1,047
1-Year High: [-----] on 2026-02-07
1-Year Low: [--] on 2025-10-12
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] +7
1-Year High: [--] on 2025-12-19
1-Year Low: [--] on 2025-12-24
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Week: [------] +203%
[--] Month: [------] -79%
[--] Months: [---------] +38%
[--] Year: [---------] +33%
1-Year High: [------] on 2025-12-22
1-Year Low: [--] on 2025-04-24
Engagements by network (24h): Reddit: [--] News: [--] X: [-----] YouTube: [--]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Week: [---] -7.90%
[--] Month: [---] +20%
[--] Months: [-----] +3%
[--] Year: [-----] +143%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-04-28
Mentions by network (24h): Reddit: [--] News: [--] X: [--] YouTube: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) in the last [--] hours which is up 27% from [--] in the previous [--] hours
Daily Average: [--]
[--] Week: [--] -13%
[--] Month: [---] +58%
[--] Months: [---] -48%
[--] Year: [-----] +147%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-04-28
The most influential creators that mention NewAmsterdam Pharma Company N.V. Ordinary Shares in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @doctorvasan | [--] | [-----] | [--] | [---] |
| @Alcorn49582 | [--] | [--] | [--] | [---] |
| @StockTickerZone | [--] | [-----] | [--] | [---] |
| @NewAmsPharma | [--] | [-----] | [--] | [---] |
| @JoseRestonVA | [--] | [-----] | [--] | [--] |
| @Lincoln49583 | [--] | [--] | [--] | [--] |
| @Biotech2k1 | [--] | [------] | [--] | [--] |
| @Grampay29346 | [--] | [--] | [--] | [--] |
| @semodough | [--] | [------] | [--] | [--] |
| @seedy19tron | [--] | [------] | [--] | [--] |
Sentiment: 73%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 73%
Daily Average: 85%
[--] Week: 33% -67%
[--] Month: 67% +17%
[--] Months: 67% -33%
[--] Year: 67% -26%
1-Year High: 100% on 2025-02-19
1-Year Low: 29% on 2025-09-24
Most Supportive Themes:
- Acquisition Rumors: (50%) Speculation about potential acquisition news is driving positive market sentiment.
- Positive Market Sentiment: (30%) The stock is trading near its 52-week high, supported by overall positive market sentiment.
Most Critical Themes:
- Recent Price Dip: (20%) Despite overall resilience, the stock experienced a slight dip in the last [--] hours.
Social Dominance: 0.00523%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00523%
Daily Average: 0.00566%
[--] Week: 0.00329% +0.00239%
[--] Month: 0.0061% +0.0022%
[--] Months: 0.0061% +0.0013%
[--] Year: 0.0061% -0.0021%
1-Year High: 0.031% on 2025-06-29
1-Year Low: 0.0012% on 2025-04-28
Market Dominance: 0.00445%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00445%
Daily Average: 0%
1-Year High: 0.18% on 2026-02-06
1-Year Low: 0.00445% on 2026-02-16
Market Cap: $3,926,723,543
Market Cap 24-Hour Time-Series Raw Data
Current Value: $3,926,723,543
Daily Average: $3,788,343,649
[--] Week: $3,949,401,703 -0.49%
[--] Month: $3,926,723,543 +9.40%
1-Year High: $4,700,048,826 on 2025-11-26
1-Year Low: $2,697,451,569 on 2025-08-28
Top NewAmsterdam Pharma Company N.V. Ordinary Shares Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"$NAMS Good reminder to always check human LOF genetics and whether your drug phenocopies known disease biology. Evolution is the longest most underappreciated clinical trial. As noted by @Biohazard3737 Good reminder to always check human LOF genetics and whether your drug phenocopies known disease biology. Evolution is the longest most underappreciated clinical trial. As noted by @Biohazard3737"
X Link @Vulpescap 2026-02-14T20:06Z [----] followers, [----] engagements
"Nearly [--] years ago statins reshaped lipid management. Since then additional therapies have expanded treatment options but many patients still do not reach recommended LDL-C goals. As we enter the next era of lipid-lowering therapy there is a meaningful opportunity to provide solutions that are effective well-tolerated and easier for patients and providers to manage helping more people achieve LDL-C levels associated with better cardiovascular health. Learn more about evolving treatment considerations and what patients and clinicians can expect next: https://www.expectmoreforldl.com/"
X Link @NewAmsPharma 2026-02-12T15:32Z [----] followers, 11.3K engagements
"Anti-Statin influencers r busy scraping the bottom of their barrels to mislead their followers. Obicetrapib the new CETPi from $NAMS is sure to silence them by its excellent safety profile & bonus benefits while raising awareness of risk posed by ldl might make it Statin [---] Do Statins make you Fat Got your attention. Good. Now hear me out. 👂👇 The new headlines around this new Lancet study screaming that millions more should be on statins and that side effects have been overblown are absurd distortions of reality. Take weight change https://t.co/xAQtMhSpH8 Do Statins make you Fat Got your"
X Link @doctorvasan 2026-02-08T19:07Z [----] followers, [---] engagements
"$NAMS will soon launch Ph 2B study for Obicetrapib in AD. If cognitive scores track biomarkers a label expansion might soon follow prior to a dedicated Ph [--] study. Widespread p-tau217's adoption will facilitate the pivot from lipid to AD prevention/Rx"
X Link @doctorvasan 2026-02-07T21:38Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing